159 related articles for article (PubMed ID: 15163657)
21. Biphasic decay of latently infected CD4+ T cells in acute human immunodeficiency virus type 1 infection.
Blankson JN; Finzi D; Pierson TC; Sabundayo BP; Chadwick K; Margolick JB; Quinn TC; Siliciano RF
J Infect Dis; 2000 Dec; 182(6):1636-42. PubMed ID: 11069234
[TBL] [Abstract][Full Text] [Related]
22. Reservoirs of human immunodeficiency virus type 1: the main obstacles to viral eradication.
Pomerantz RJ
Clin Infect Dis; 2002 Jan; 34(1):91-7. PubMed ID: 11731950
[TBL] [Abstract][Full Text] [Related]
23. Latent reservoirs of HIV: obstacles to the eradication of virus.
Chun TW; Fauci AS
Proc Natl Acad Sci U S A; 1999 Sep; 96(20):10958-61. PubMed ID: 10500107
[TBL] [Abstract][Full Text] [Related]
24. HIV-1 can be recovered from a variety of cells including peripheral blood monocytes of patients receiving highly active antiretroviral therapy: a further obstacle to eradication.
Crowe SM; Sonza S
J Leukoc Biol; 2000 Sep; 68(3):345-50. PubMed ID: 10985250
[TBL] [Abstract][Full Text] [Related]
25. Epigenetic regulation of HIV-1 persistence and evolving strategies for virus eradication.
Dhamija N; Rawat P; Mitra D
Subcell Biochem; 2013; 61():479-505. PubMed ID: 23150264
[TBL] [Abstract][Full Text] [Related]
26. The latent HIV-1 reservoir in patients undergoing HAART: an archive of pre-HAART drug resistance.
Noë A; Plum J; Verhofstede C
J Antimicrob Chemother; 2005 Apr; 55(4):410-2. PubMed ID: 15728140
[TBL] [Abstract][Full Text] [Related]
27. Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus.
Chun TW; Justement JS; Moir S; Hallahan CW; Maenza J; Mullins JI; Collier AC; Corey L; Fauci AS
J Infect Dis; 2007 Jun; 195(12):1762-4. PubMed ID: 17492591
[TBL] [Abstract][Full Text] [Related]
28. Latency: the hidden HIV-1 challenge.
Marcello A
Retrovirology; 2006 Jan; 3():7. PubMed ID: 16412247
[TBL] [Abstract][Full Text] [Related]
29. Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4(+) T cells from HIV-1-infected HAART-treated patients.
Bouchat S; Gatot JS; Kabeya K; Cardona C; Colin L; Herbein G; De Wit S; Clumeck N; Lambotte O; Rouzioux C; Rohr O; Van Lint C
AIDS; 2012 Jul; 26(12):1473-82. PubMed ID: 22555163
[TBL] [Abstract][Full Text] [Related]
30. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.
Zhang L; Ramratnam B; Tenner-Racz K; He Y; Vesanen M; Lewin S; Talal A; Racz P; Perelson AS; Korber BT; Markowitz M; Ho DD
N Engl J Med; 1999 May; 340(21):1605-13. PubMed ID: 10341272
[TBL] [Abstract][Full Text] [Related]
31. Human immunodeficiency virus type 1 (HIV-1) antigen secretion by latently infected resting CD4+ T lymphocytes from HIV-1-infected individuals.
Fondere JM; Petitjean G; Huguet MF; Salhi SL; Baillat V; Macura-Biegun A; Becquart P; Reynes J; Vendrell JP
J Virol; 2004 Oct; 78(19):10536-42. PubMed ID: 15367620
[TBL] [Abstract][Full Text] [Related]
32. Latently infected cell activation: a way to reduce the size of the HIV reservoir?
Forde J; Volpe JM; Ciupe SM
Bull Math Biol; 2012 Jul; 74(7):1651-72. PubMed ID: 22562387
[TBL] [Abstract][Full Text] [Related]
33. Molecular biological assessment methods and understanding the course of the HIV infection.
Katzenstein TL
APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
[TBL] [Abstract][Full Text] [Related]
34. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy.
Finzi D; Blankson J; Siliciano JD; Margolick JB; Chadwick K; Pierson T; Smith K; Lisziewicz J; Lori F; Flexner C; Quinn TC; Chaisson RE; Rosenberg E; Walker B; Gange S; Gallant J; Siliciano RF
Nat Med; 1999 May; 5(5):512-7. PubMed ID: 10229227
[TBL] [Abstract][Full Text] [Related]
35. A novel approach to HIV therapy: highly active antiretroviral therapy and autologous hematopoietic cell transplantation.
Pippi F
Med Hypotheses; 2008; 70(2):291-3. PubMed ID: 17681707
[TBL] [Abstract][Full Text] [Related]
36. Epigenetics of HIV infection: promising research areas and implications for therapy.
Ay E; Banati F; Mezei M; Bakos A; Niller HH; Buzás K; Minarovits J
AIDS Rev; 2013; 15(3):181-8. PubMed ID: 24002202
[TBL] [Abstract][Full Text] [Related]
37. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy.
Chun TW; Davey RT; Ostrowski M; Shawn Justement J; Engel D; Mullins JI; Fauci AS
Nat Med; 2000 Jul; 6(7):757-61. PubMed ID: 10888923
[TBL] [Abstract][Full Text] [Related]
38. Hide-and-seek: the challenge of viral persistence in HIV-1 infection.
Geeraert L; Kraus G; Pomerantz RJ
Annu Rev Med; 2008; 59():487-501. PubMed ID: 17845138
[TBL] [Abstract][Full Text] [Related]
39. Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study.
Routy JP; Tremblay CL; Angel JB; Trottier B; Rouleau D; Baril JG; Harris M; Trottier S; Singer J; Chomont N; Sékaly RP; Boulassel MR
HIV Med; 2012 May; 13(5):291-6. PubMed ID: 22276680
[TBL] [Abstract][Full Text] [Related]
40. Administration of HDAC inhibitors to reactivate HIV-1 expression in latent cellular reservoirs: implications for the development of therapeutic strategies.
Demonté D; Quivy V; Colette Y; Van Lint C
Biochem Pharmacol; 2004 Sep; 68(6):1231-8. PubMed ID: 15313421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
